FLGT
Fulgent Genetics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$19.73
+0.41%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 323.9M | 322.7M | 283.5M | 289.2M | 619.0M |
| Cost of Revenue | 208.7M | 191.8M | 176.3M | 184.8M | 252.1M |
| Gross Profit | 115.3M | 130.9M | 107.2M | 104.5M | 366.9M |
| Operating Expenses | |||||
| R&D Expense | 56.8M | 53.9M | 48.8M | 41.4M | 28.9M |
| SG&A Expense | 169.9M | 160.0M | 124.4M | 130.5M | 150.0M |
| General & Admin Expense | 119.9M | 116.7M | 88.1M | 89.0M | 111.1M |
| Selling & Marketing Expense | 50.1M | 43.4M | 36.2M | 41.5M | 38.9M |
| Other Expenses | 8.7M | 8.0M | 8.0M | 128.1M | 9.5M |
| Total Operating Expenses | 235.4M | 222.0M | 181.1M | 300.0M | 188.4M |
| Cost and Expenses | 444.0M | 413.8M | 357.4M | 484.7M | 440.4M |
| Operating Income (EBIT) | (120.1M) | (91.1M) | (73.9M) | (195.5M) | 178.5M |
| Non-Operating | |||||
| Interest Income | 29.9M | 30.9M | 31.3M | 21.6M | 5.6M |
| Interest Expense | 238.0K | 75.0K | 170.0K | 488.0K | 1.0M |
| Net Interest Income | 29.6M | 30.8M | 31.1M | 21.1M | 4.6M |
| Other Non-Op Income/Expense | 29.0M | 21.1M | 22.0M | 21.4M | 5.5M |
| Non-Operating Income (excl Interest) | (29.3M) | (21.1M) | (22.1M) | (21.9M) | (6.5M) |
| EBT (Pre-Tax Income) | (91.1M) | (70.0M) | (52.0M) | (174.1M) | 184.0M |
| Income Tax Expense | (5.6M) | (8.4M) | (8.1M) | 1.2M | 42.1M |
| Bottom Line | |||||
| Net Income | (84.4M) | (60.5M) | (42.7M) | (167.8M) | 143.4M |
| Earnings from Cont. Ops | (85.5M) | (61.6M) | (43.8M) | (175.2M) | 141.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (84.4M) | (60.5M) | (42.7M) | (167.8M) | 143.4M |
| Per Share | |||||
| Basic EPS | ($2.82) | ($1.97) | ($1.41) | ($5.63) | $4.76 |
| Diluted EPS | ($2.82) | ($1.97) | ($1.41) | ($5.63) | $4.63 |
| Revenue Per Share | $11.57 | $10.48 | $9.38 | $9.71 | $20.57 |
| Shares | |||||
| Basic Shares Outstanding | 28.0M | 30.8M | 30.2M | 29.8M | 30.1M |
| Diluted Shares Outstanding | 28.0M | 30.8M | 30.2M | 29.8M | 31.0M |
| Profitability Metrics | |||||
| EBITDA | (65.0M) | (45.8M) | (26.9M) | (147.5M) | 217.7M |
| D&A | 25.8M | 24.1M | 24.9M | 26.1M | 32.7M |
| EBIT | (90.8M) | (70.0M) | (51.8M) | (173.6M) | 185.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026